Are you a Fellow?

Membership is now FREE for Fellows.

To join, visit our membership page.
Northern California CASIPP Fellow Cadaver Course - May 12, 2018

Message from Course Directors Dr. Samir Sheth and Dr. Vafi Salmasi:

This past May, CASIPP held its first Northern California fellow cadaver course. With the help of the esteemed faculty – Dr. Lawrence Poree, Dr. Ruben Kalra, Dr. Line Jacque, Dr. Mark Wallace, Dr. Scott Pritzlaff, Dr. Ramo Naidu, Dr. Eric Lee, Dr. Charles DeMesa, Dr. Lisa Kroopf, Dr. Vafi Salmasi and Dr. Samir Sheth and our industry support from Boston Scientific, Nuvectra, Medtronic, Nevro, Stimwave, SPR therapeutics, Bioness and Abbott – CASIPP’s fellow cadaver course went extremely well and was very well received. The morning consisted of 5 didactic lectures covering fundamental spinal cord, dorsal root ganglion and peripheral nerve stimulation principles followed by a lively panel discussion. The afternoon consisted of cadaver stations focusing on refining neuromodulation techniques. There was also a live model for ultrasound to complement the cadaveric peripheral nerve station.

Dr. Samir Sheth and Dr. Vafi Salmasi, as course directors, would like to extend a big thank you to the faculty, the industry sponsorship and to Dr. Jason Pope and Stephanie Aycock.

President-Elect Announced

Jason Pope, MD is the current President of CASIPP and began his term after the 8th Annual Meeting concluded.

2018 Annual Meeting Announced

Our 9th annual meeting took place November 2-4, 2018 at the at the luxurious Ritz-Carlton Bacara Resort in Santa Barbara, California. Once again, we provided relevant, up-to-date lectures and valuable networking opportunities for pain management practitioners and staff. Save the date for next year’s event in Tahoe. Oct 24-27, 2019

Learn More >

CURES Update

Notice from the Medical Board of California:

CURES 2.0 mandatory use began October 2, 2018.

CURES Mandatory Use

The Controlled Substance Utilization Review and Evaluation System (CURES) was certified for statewide use by the Department of Justice (DOJ) on April 2, 2018. Therefore, the mandate to consult CURES prior to prescribing, ordering, administering, or furnishing a Schedule II–IV controlled substance became effective October 2, 2018. Here is everything you need to know.

When must I consult CURES?

  • The first time a patient is prescribed, ordered, administered, or furnished a controlled substance, unless one of the exemptions below apply.
  • Within the twenty-four hour period, or the previous business day, before prescribing, ordering, administering, or furnishing a controlled substance, unless one of the exemptions below apply.
  • Before subsequently prescribing a controlled substance, if previously exempt.
  • At least once every four months if the controlled substance remains a part of the patient’s treatment plan.

Note: The phrase “controlled substance” as used in the guide refers to a Schedule II, Schedule III, or Schedule IV controlled substance.

“First time” is defined as the initial occurrence in which a health care practitioner intends to prescribe, order, administer, or furnish a controlled substance to a patient and has not previously prescribed a controlled substance to the patient.

— Health and Safety Code (HSC), § 11165.4(a)(1)(B)

www.mbc.ca.gov/cures